CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Pazopanib Hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00861913
NCT00861913Phase 2Completed
CompareCT.gov

Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients

National Cancer Institute (NCI)·interventional·Posted Mar 16, 2009·Updated Oct 16, 2018

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pazopanib Hydrochloride, and 1 other intervention for Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7. Completed, enrolled 13 participants across 4 sites.

Detailed Summary

This phase II trial is studying the side effects of pazopanib hydrochloride and to see how well it works in treating patients with metastatic melanoma that cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 16, 2009
Enrollment StartApr 3, 2009
Primary CompletionSep 14, 2010
Study CompletionJan 16, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.3 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pazopanib Hydrochloridedrug

Given orally

Pharmacological Studyother

Correlative studies